Key result
African-origin patients had a significantly higher rate of abnormal aldosterone/renin ratio compared to European-origin patients (55.6% vs 22.6%, P<0.001).
Why the study?
The aldosterone/renin ratio is the initial screening test for primary hyperaldosteronism, but little data exists regarding ethnic variations in this.
Does African origin increase the rate of abnormal aldosterone/renin ratio compared to European origin in patients screened for primary hyperaldosteronism?
Observational (n=1,473)
No
Does African origin increase the rate of abnormal aldosterone/renin ratio compared to European origin in patients screened for primary hyperaldosteronism?
Absolute Event Rate: 55.6% vs 22.6%
p-value: p=< 0.001
African-origin patients have a significantly higher prevalence of abnormal aldosterone/renin ratio compared to European-origin patients, suggesting a need to reevaluate current screening guidelines for this population.
ARR abnormalities more common in African-origin patients; hypothesis-generating for ethnicity-specific PHA screening thresholds.
INTRODUCTION: The aldosterone/renin ratio is the initial screening test for primary hyperaldosteronism (PHA), but little data exists regarding ethnic variations in this. METHODS: Following clinical observation of a high prevalence of abnormal aldosterone/renin ratio (ARR) in patients of African-origin, we retrospectively reviewed all ARR measurements in a single centre over 10 years. Rates of hypokalaemia, intraventricular septal thickness (IVS, by echocardiography) and adrenal imaging were recorded when available. RESULTS: Aldosterone/renin ratio was available in 1473 patients, and abnormal in 374 (25.4%). Abnormal ARR was observed in 305/1349 (22.6%) of European-origin and 69/124 (55.6%) of African-origin patients (P < 0.001). Among those with abnormal ARR, hypokalaemia (<3.5 mmol/L) was documented on at least one occasion in 171/305 (56.1%) European-origin and 43/69 (62.3%) African-origin patients (P = 0.35). Median (range) IVS was 1.57 (0.78-2.80) cm in African-origin and 1.20 (0.69-2.18) cm in European-origin patients (P < 0.002); IVS did not correlate with aldosterone or ARR however. Adrenal adenoma was identified in 41/170 (24.1%) of European-origin and 4/29 (13.7%) African-origin patients (P = 0.15), while hyperplasia was identified in 35/170 (20.5%) of European and 8/29 (27.5%) African patients (P = 0.39). CONCLUSION: In summary, ARR was abnormal in 55.6% of African-origin patients screened at an Irish hospital. Rates of hypokalaemia were similar between European-origin and African-origin patients. These findings have implications for the use of current screening guidelines for ARR in African-origin patients and also for the mechanistic role of aldosterone in hypertensive complications in African-origin patients.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2018) conducted an observational in Primary hyperaldosteronism screening (n=1,473). African-origin vs. European-origin was evaluated on Abnormal aldosterone/renin ratio (p=< 0.001). African-origin patients had a significantly higher rate of abnormal aldosterone/renin ratio compared to European-origin patients (55.6% vs 22.6%, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: